XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Recommendation of “Hold” by Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $53.75.

A number of brokerages recently issued reports on XOMA. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Lucid Cap Mkts downgraded shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Benchmark lowered shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. Finally, HC Wainwright cut shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research note on Thursday, April 30th.

XOMA Royalty Stock Performance

NASDAQ:XOMA opened at $40.17 on Friday. The stock has a 50-day simple moving average of $41.86 and a two-hundred day simple moving average of $34.61. XOMA Royalty has a 52-week low of $22.29 and a 52-week high of $45.22. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59. The firm has a market capitalization of $503.77 million, a PE ratio of 25.59 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The company had revenue of $12.32 million during the quarter, compared to analysts’ expectations of $13.91 million. Analysts forecast that XOMA Royalty will post 0.9 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares during the period. State of Alaska Department of Revenue bought a new position in shares of XOMA Royalty in the fourth quarter worth about $27,000. Dimensional Fund Advisors LP grew its position in shares of XOMA Royalty by 4.5% during the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after purchasing an additional 1,269 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.